期刊文献+

温肾散结法联合西药治疗乳腺癌骨转移疼痛临床研究 被引量:3

Clinical Study of Wenshen Sanjie Method Combined with Western Medicine to Treat Breast Cancer with Bone Metastasis Pain
下载PDF
导出
摘要 目的:观察温肾散结法联合化疗、双磷酸盐治疗乳腺癌骨转移疼痛的效果。方法:31例乳腺癌骨转移伴有疼痛患者按随机数字表法分成对照组和治疗组。对照组应用双磷酸盐和化疗,治疗组在对照组的基础上加用温肾散结方药,对照组仅用唑来膦酸和TP方案化疗。治疗2周期进行疗效评价。结果:治疗组镇痛效果、生活质量评分及体质量增加稳定率优于对照组(P<0.05)。治疗组治疗后外周血WBC、Hb、PLT稍降低(P>0.05),对照组治疗后上述指标明显下降(P<0.05)。结论:温肾散结方药联合化疗、双磷酸盐治疗乳腺癌骨转移疼痛止痛效果良好,可以改善患者生活质量,减轻化疗的毒副作用。 Objective:To observe the clinical therapeutic effects of Wenshen Sanjie Method combined with western medicine treat breast cancer with matastasis of bone.Methods:A random sample of patients were divided into the treatment group and control group.Both groups were treated with biphosphonate and chemotherapy;the treatment group was treated with adding Wenshen Sanjie Method;the control group was treated with biphosphonate and chemotherapy.The clinical efficacy was evaluated after two cycles of chemotherapy.Results:The effect of analgesia,score of life quality and body quality of the treatment group were better than those of control group(P0.05).Amount of WBC,Hb and PLT in Peripheral blood of treatment group was more than those of control group(P0.05).Conclusion:Wenshen Sanjie Method combined with chemotherapy in treating breast cancer with matastasis of bone can improve their quality of life,relieve bone pain and side and toxic effects caused by chemotherapy.
出处 《中医学报》 CAS 2011年第10期1158-1159,共2页 Acta Chinese Medicine
关键词 乳腺癌 骨转移 疼痛 温肾散结 breast cancer matastasis of bone pain wenshen sanjie method
  • 相关文献

参考文献3

二级参考文献12

  • 1[3]Ware JE Jr,Sherbourne CD.The MOS 36-item Short-Form Health Survey(SF-36).L Conceptual framework and item selection.Med Care 1992;30(6):473-83 被引量:1
  • 2[4]Rubens,Fogelmen.Bone Metastases//Langlais F,Tomeno B.Limb Salvage.Major Reconstruction in Oncologic and Nontumoral Conditions.New York:Springer 1991:121-42 被引量:1
  • 3Saad F,Gleason DM,Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer[ J ]. Nad Cancer Inst, 2004,96 ( 11 ): 879 ~882. 被引量:1
  • 4Saad F, Gleason DM, Murray R, et al. The role of bisphosphonates in breast cance[J].Natl Cancer Inst,2002,94(19) :1 458~ 1 468. 被引量:1
  • 5Coleman RE. Bisphosphonates: clinical experience [J]. Oncologist, 2004,9(4): 14 ~ 27. 被引量:1
  • 6Vogel CL, Yanagihara RH, Wood AJ, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy[J]. Oncologist,2004,9(6) :687 ~ 695. 被引量:1
  • 7Lipton A.Toward new horizons: the future of bisphosphonate therapy[ J ].Oncologist, 2004,9(4): 38 ~ 47. 被引量:1
  • 8李志革,廖萍,胡晓桦.帕米膦酸二钠(博宁)治疗癌症骨痛的疗效观察[J].中国肿瘤临床与康复,1999,6(1):86-87. 被引量:14
  • 9解温品,刁宏山,费立国.心理干预在癌性疼痛治疗中的应用[J].中国医师杂志,2003,5(1):99-99. 被引量:9
  • 10王岭,王臻,凌瑞,姚青,刘继中.外科治疗对晚期乳腺癌骨转移患者生活质量的影响[J].中国临床康复,2003,7(11):1674-1675. 被引量:5

共引文献61

同被引文献56

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部